Philip H. Abbosh
ORCID: 0000-0003-3611-9532Also affiliated with Einstein Healthcare Network, Cancer Research Center
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 6 papers. Top paper: “Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)”.
Philip H. Abbosh, Eric A. Ross, Matthew R. Zibelman, Pooja Ghatalia, Fern Anari +14 more
Henkel Valentine, David Liu, Michael J. Slifker, Costas D. Lallas, Edouard J. Trabulsi +24 more
Nagib Ahsan, Amriti R. Lulla, Avital Lev, Philip H. Abbosh, David T. Dicker +3 more
Nagib Ahsan, Amriti R. Lulla, Avital Lev, Philip H. Abbosh, David T. Dicker +3 more
Megan Prunty, Ilaha Isali, Adam Calaway, Rashida Ginwala, Mohit Sindhani +7 more
Rashida Ginwala, Mohit Sindhani, Megan Prunty, Daniel M. Geynisman, Pooja Ghatalia +15 more